PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERS

• US 20150258115A1
• Filed: 05/18/2015
• Published: 09/17/2015
• Est. Priority Date: 03/18/2011
• Status: Active Grant

• Current Assignee: Alkermes Pharma Ireland Limited (Alkermes plc)
• Original Assignee: Alkermes Pharma Ireland Limited (Alkermes plc)
• Inventors: Perry, Jason M., Deaver, Daniel R., Hickey, Magali B., Remenar, Julius F., Vandiver, Jennifer
• Granted Patent: US 9,351,976 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/4965 Non-condensed pyrazines
• CPC Class Codes: A61K 31/497 containing further heterocyclic rings
• CPC Class Codes: A61K 31/551 having two nitrogen atoms, e.g. dilazep
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/24 Antidepressants

Abstract

The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.

Claims

1-40. -40. (canceled)

41. A pharmaceutical composition comprising:

(a) compound of Formula (III) or (IV);

42. The composition of claim 41, wherein the composition comprises components (b) and (c) at a ratio that results in flocs comprising component (a), wherein the flocs settle to greater than a predetermined sediment bed height, such that components (a), (b) and (c) can be resuspended for injection.

43. The composition of claim 42, wherein the bed height is comprised of at least a 20 to 80% increase in sediment height compared to a non flocculated composition after 24 hours of undisturbed sitting.

44. The composition of claim 42, wherein components (a), (b) and (c) can be resuspended for injection within 1-60 seconds of handshaking.

45. The composition of claim 41, wherein the ratio of components (b) to (c) is such that the composition can be injected using a 20 to 25 gauge needle.

46. The composition of claim 42, wherein (a), (b), and (c) form flocs having the following sizes:

Dv[10];

2-10 μ

m, Dv[50];

10-30 μ

m, and Dv[90];

less than 65 μ

mM.

47. The composition of claim 41, wherein the ratio of components (b) to (c) is approximately 5 to 2, by weight.

48. The composition of claim 41, comprising about 0.2-1 weight percent sorbitan laurate.

49. The composition of claim 41, comprising about 0.4-0.7 weight percent sorbitan laurate.

50. The composition of claim 41, comprising about 0.5 weight percent sorbitan laurate.

51. The composition of claim 41, comprising about 0.05-0.8 weight percent polysorbate 20.

52. The composition of claim 41, comprising about 0.1-0.3 weight percent polysorbate 20.

53. The composition of claim 41, comprising about 0.2 weight percent polysorbate 20.

54. The composition of claim 41, comprising approximately 15-35 weight percent compound of formula III or IV.

55. The composition of claim 41, comprising approximately 20-30 weight percent compound of formula III or IV.

59. A method for treating disorders of the central nervous system, comprising administering an effective amount of the composition of claim 41 to an individual in need of such treatment.

60. The method of claim 59, wherein the disorder is selected from the group consisting of anxiety, depression, bipolar disorder, autism-related irritability, and a psychotic condition.

56. An injectable pharmaceutical composition comprising:

(a) a compound of formula III or IV;

57. An injectable composition comprising:

(a) a compound of formula III or IV;

58. The composition of claim 57, wherein the composition is formulated for modulating tissue reaction associated with the delivery of a water-insoluble antipsychotic agent.